智通财经APP获悉，维亚生物(01873)再涨超5%，截至发稿，涨4.44%，报2.59港元，成交额2025.89万港元。
广发证券发布研报称，近期全球AI制药新增多单合同；大型制药公司越来越清晰地认识到AIDD的战略价值；近期多起事件共同反映出，AI制药从概念期逐步进入实质落地与平台化应用阶段。该行预计，明年年中AIDD行业加速发展的趋势将更加明显。
国元国际此前指出，维亚生物自5年前已经布局AI制药，目前AI订单占比：AI相关订单占比达到新签订单的12%，且呈增长趋势。华鑫证券则表示，维亚生物CRO业务主要服务于药物发现的早期，是AI应用的重要场景，可提升药物研发的效率和成功率，因此公司为客户推出了整合了AI的药物研发平台——AIDD，截止2025年上半年，AIDD已累计参与175个项目的开发，AI赋能的CRO业务占总收入的10%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.